FMP

FMP

Enter

BLTE - Belite Bio, Inc

photo-url-https://images.financialmodelingprep.com/symbol/BLTE.png

Belite Bio, Inc

BLTE

NASDAQ

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

56.21 USD

3.17 (5.64%)

Latest BLTE News

GlobeNewsWire

Aug 5, 2024

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the second quarter ended June 30, 2024.

Read More

Seeking Alpha

May 14, 2024

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio, Inc. (NASDAQ:BLTE ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Yi Chen - H. C. Wainwright Basma Radwan - Leerink Partners Operator Hello, and thank you for joining us to discuss Belite Bio's First Quarter 2024 Financial Results.

Read More

Zacks Investment Research

Apr 10, 2024

Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?

The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More

Seeking Alpha

Mar 12, 2024

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Read More

GlobeNewsWire

Mar 6, 2024

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, March 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2023.

Read More

GlobeNewsWire

Feb 7, 2024

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place ...

Read More

Seeking Alpha

Nov 14, 2023

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Kento Basma Radwan - Leerink Partners Yi Chen - HC Wainwright Bruce Jackson - The Benchmark Company Operator Hello and thank you for joining us to discuss Belite's Third Quarter 2023 Financial Results. Joining the...

Read More

GlobeNewsWire

Nov 7, 2023

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company's financial results for the third quarter ended September 30, 2023, and provide a general business update.

Read More

Zacks Investment Research

Aug 21, 2023

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Read More

Seeking Alpha

Aug 13, 2023

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

Belite Bio, Inc (NASDAQ:BLTE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Fitzgerald & Co. Yi Chen - HC Wainwright & Co, LLC Bruce Jackson - The Benchmark Company Operator Good morning, and welcome to the Belite Bio Q2 2023 Financial Results Conference...

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep